Listing 1 - 10 of 573 | << page >> |
Sort by
|
Choose an application
Choose an application
Choose an application
Choose an application
Prostate --- Prostate-specific antigen. --- PSA (Antigen) --- Tumor antigens --- Cancer --- Diagnosis.
Choose an application
L'objectif de ce projet est de développer un nouveau traitement d'immunothérapie contre le cancer du poumon. Le traitement consistera en l'administration pulmonaire de liposomes contenant des antigènes tumoraux et du CpG ODN, un adjuvant. La forme liposomale devrait permettre de viser des cellules présentatrices d'antigènes telles que les cellules dendritiques. L'administration locale du CpG et des antigènes devrait aussi permettre une meilleure efficacité du traitement.Ma contribution à cette étude a consisté en la formulation et la caractérisation de liposomes encapsulant les antigènes tumoraux spécifiques. Deux peptides antigéniques ont été sélectionnés : le GplOO 209-217 (2M) et le Melan-A 26-35 (2L). Ce sont tous les deux des épitopes immunogéniques reconnus par les lymphocytes T. Ils ont été modifiés pour augmenter leur immunogénicité. Les formulations de liposomes devaient suivre certains critères. Leur taille devait se situer en dessous de 200 nm pour échapper aux macrophages alvéolaires. Les liposomes devaient être stables et avoir un taux élevé de chargement en antigènes. Une technique HPLC a été mise au point pour le dosage des antigènes. Plusieurs techniques ont été utilisées au cours de l'étude pour améliorer les formulations de liposomes et pour permettre la co-encapsulation avec le CpG : !'hydratation de film comparée à l'injection d'éthanol ou encore l'adsorption des antigènes comparée à leur encapsulation. Afin d'augmenter le chargement en antigènes, la composition en lipides cationiques a été augmentée.Deux formulations de liposomes ont été sélectionnées au terme de mon travail. Elles sont composées respectivement de DOTAP-DPPC et de DC-Chol-DPPC à une proportion 3 :1. Elles sont préparées respectivement par hydratation de film et injection d'éthanol avec 200 µg/mL de GplOO 209-217 (2m) et Melan-A 26-35 (2L). Elles ont permis avec succès la co encapsulation avec l'adjuvant, le CpG C274 et seront utilisées pour l'étude in vivo sur des souris C57Bl/6NRJ porteuses de tumeurs B16F10. The aim of this project is to develop a new immunotherapy approach against lung cancer.The treatment will consist of the pulmonary administration of liposomes-encapsulated tumor antigens and CpG ODN. Liposomes should allow the targeting of antigen presenting cells such as dendritic cells. The local delivery of CpG oligonucleotides and antigens should also increase their therapeutic efficacy.My input in this project was to formulate and characterize liposomes encapsulating the tumor specific antigens. Two antigenic peptides were selected: Gp100 209-217 (2M) and Melan-A 26-35 (2L). They are both immunogenic epitopes that are recognized by T cells and that have been modified in order to increase their immunogenicity.The liposomes formulations had to follow a set of criteria. The size of the liposomes had to be less than 200 nm in order to prevent alveolar macrophage uptake. The liposomes had to be stable and have a high peptide loading rate. An HPLC technique has been developed for the antigen quantification.Several techniques have been used throughout the study to improve the liposome formulations and to allow the co-encapsulation with the CpG: film hydration vs ethanol injection and antigen adsorption vs encapsulation. In order to improve the antigen loading rate, of cationic lipids was increased.Two liposomes formulations were selected at the end of my work. They are respectively made up of DOTAP-DPPC and CD-Chol-DPPC in a 3:1 proportion. They are prepared respectively by film hydration and ethanol injection with a 200µg/mL concentration of Gp100 209-217 (2M) and Melan-A 26-35 (2L). They have led to a successful co-encapsulation with the adjuvant, CpG C274, and will be used in the in-vivo study on B16F10tumor bearing C57B1/6NRJ mice.
Liposomes --- gp100 Melanoma Antigen --- MART-1 Antigen --- Lung Neoplasms --- Immunotherapy
Choose an application
Choose an application
Choose an application
Choose an application
The Natural Anti-Gal Antibody as Foe Turned Friend in Medicine provides a comprehensive review of the natural anti-Gal antibody, which is the most abundant antibody in humans constituting ~1% of immunoglobulins and the carbohydrate antigen it recognizes, the?-gal epitope. It discusses the discovery of this antigen/antibody system, its evolution in mammals, the pathological effects of this antibody, and its possible use in various therapies in humans. Most significantly, the book discusses microbial and regenerative therapies in which an antibody present in all humans may be harnessed as an in vivo pharmaceutical agent that enables a wide variety of therapies. Some of these therapies are described as experimental studies that are compiled in this book, other already studied therapies in the area of cancer immunotherapy are also included in this book.
Choose an application
Dendritic Cells, 2nd Edition is the new edition of the extremely successful book published in 1998. With the volume of literature on dendritic cells doubling every year, it is almost impossible to keep up. This book provides the most up-to-date synthesis of the literature, written by the very best authors. It is essential reading for any scientist working in immunology, cell biology, infectious diseases, cancer, transplantation, genetic engineering, or the pharmaceutical/biotechnology industry.* An entirely new section on DC biology is included in this edition. Also new to this
Listing 1 - 10 of 573 | << page >> |
Sort by
|